Manchester Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$56.4K Hold
300
0.01% 465
2025
Q4
$56.8K Hold
300
0.01% 470
2025
Q3
$49.7K Hold
300
0.01% 569
2025
Q2
$46K Hold
300
0.01% 580
2025
Q1
$47.2K Hold
300
0.01% 560
2024
Q4
$47.1K Hold
300
0.01% 548
2024
Q3
$53.2K Hold
300
0.01% 528
2024
Q2
$50.5K Buy
+300
New +$49.1K 0.01% 503
2014
Q4
Sell
-1,780
Closed -$188K 1108
2014
Q3
$188K Hold
1,780
0.03% 360
2014
Q2
$170K Hold
1,780
0.02% 408
2014
Q1
$162K Hold
1,780
0.03% 386
2013
Q4
$158K Buy
+1,780
New +$149K 0.02% 384

Other funds holding BBH

Manchester Capital Management's BBH Position: Q1 2026 in Review

Manchester Capital Management held its VanEck Biotech ETF (BBH) position steady in Q1 2026 at 300 shares worth $56.4K. The position accounts for 0.01% of the portfolio, ranked #465.

Manchester Capital Management first reported a position in BBH in Q4 2013 and has held it in 12 quarters since. The position peaked at $188K in Q3 2014. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

  • Manchester Capital Management held 300 shares of VanEck Biotech ETF worth $56.4K as of Q1 2026.
  • Manchester Capital Management left its VanEck Biotech ETF share count unchanged in Q1 2026.
  • VanEck Biotech ETF made up 0.01% of Manchester Capital Management's portfolio in Q1 2026, its #465 holding.
  • Manchester Capital Management first reported a position in VanEck Biotech ETF in Q4 2013 and has held it in 12 quarters since.
  • Manchester Capital Management's VanEck Biotech ETF position peaked at $188K in Q3 2014.
  • 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.